ArticleScientific reports2025
A novel double machine learning approach for detecting early breast cancer using advanced feature selection and dimensionality reduction techniques.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
- Optimized KNN with domain-informed features and LIME explainability for improved breast cancer classification.BMC medical informatics and decision making · 2026Article
- An Integrated Statistical and Machine Learning Approach for Breast Cancer Classification Using Tumor Morphological Features.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this paper, three Double Machine Learning (DML) models are proposed to enhance the accuracy of breast cancer detection using machine learning techniques using breast cancer detection dataset. The DML models learn the primary features using machine learning and deep learning models. Then, these features are fused by a meta-classifier to achieve the best classification performance. The first DML model combines the interpretability of Random Forest (RF) with the deep learning capabilities of a Feedforward Neural Network (FNN). RF processes structured features, providing class probabilities and feature importance scores, while the FNN learns non-linear relationships and generates embeddings. These outputs are fused into a combined feature vector, which is then used by a meta-classifier for final predictions. This approach effectively captures both structured features and non-linear patterns, making it suitable for datasets with complex dependencies. The second model pairs eXtreme Gradient Boosting (XGBoost), a highly efficient boosting algorithm for tabular data, with an Artificial Neural Network (ANN). XGBoost optimizes decision tree ensembles and provides class probabilities, while the ANN processes numerical data to learn deeper representations. A meta-classifier then uses the fused outputs from both XGBoost and ANN for final predictions. This model is particularly effective for datasets combining structured features (handled by XGBoost) with numerical features (handled by ANN). The third model integrates LightGBM, a fast and scalable gradient-boosting framework, with an ANN, which is well-suited for analyzing sequential data. LightGBM processes structured features to provide probabilities and importance scores, while the ANN learns temporal dependencies from sequential data. The outputs from LightGBM and ANN are concatenated and passed into a meta-classifier for decision-making. This model is ideal for datasets with both static features (LightGBM) and continuous data (ANN), such as time-series datasets or datasets with sequential dependencies. These DML models, when combined with dimensionality reduction (PCA) and feature selection, significantly improve the performance of breast cancer detection systems by leveraging both structured and sequential data with high accuracy of 0.99.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.